Inhibitory effects of Tomivosertib in acute myeloid leukemia

The MAPK-interacting kinases 1 and 2 (MNK1/2) have generated increasing interest as therapeutic targets for acute myeloid leukemia (AML). We evaluated the therapeutic potential of the highly-selective MNK1/2 inhibitor Tomivosertib on AML cells. Tomivosertib was highly effective at blocking eIF4E pho...

Descripción completa

Detalles Bibliográficos
Autores principales: Suarez, Milagros, Blyth, Gavin T., Mina, Alain A., Kosciuczuk, Ewa M., Dolniak, Blazej, Dinner, Shira, Altman, Jessica K., Eklund, Elizabeth A., Saleiro, Diana, Beauchamp, Elspeth M., Platanias, Leonidas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121614/
https://www.ncbi.nlm.nih.gov/pubmed/34012509
http://dx.doi.org/10.18632/oncotarget.27952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121614/
https://www.ncbi.nlm.nih.gov/pubmed/34012509
http://dx.doi.org/10.18632/oncotarget.27952

Ejemplares similares